The first in-human phase 1 trial (NCT02099058) evaluated Teliso-V in advanced NSCLC with c-MET overexpression tumors (c-Met-positive; immunohistochemistry membrane H-score ≥ 150) that progressed despite standard therapy [39]. Here, MET is linked to non-small cell lung carcinoma.